Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety,
pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of
ORIC-533 in patients with multiple myeloma who have exhausted available treatment options